CTI Plans Label Expansion For Zevalin After Acquiring The NHL Drug From Biogen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Therapeutics plans to initiate two clinical trials evaluating the use of the non-Hodgkin's B-cell lymphoma drug Zevalin (ibritumomab tiuxetan) in front-line lymphoma settings to drive revenues of the product after acquiring it from Biogen Idec. The company announced plans to buy Zevalin for $30 million in up-front and milestone payments Aug. 16
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.